{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:14:13Z","timestamp":1793726053138,"version":"4.6.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"American Academy of Neurology Foundation"},{"DOI":"10.13039\/100003157","name":"Myasthenia Gravis Foundation of America","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100003157","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Duke Translational Research Institute","award":["UL1RR024128"],"award-info":[{"award-number":["UL1RR024128"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.jaut.2013.12.005","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T22:00:20Z","timestamp":1388786420000},"page":"130-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis"],"prefix":"10.1016","volume":"52","author":[{"given":"J.S.","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Guidon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.C.","family":"Juel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.B.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.J.","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.","family":"Guptill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2013.12.005_bib1","series-title":"Neurology in clinical practice","article-title":"Disorders of neuromuscular transmission","author":"Meriggioli","year":"2012"},{"key":"10.1016\/j.jaut.2013.12.005_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaut.2013.12.005_bib3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","article-title":"Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience","volume":"41","author":"Pasnoor","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaut.2013.12.005_bib4","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/01.WNL.0000150587.71497.B6","article-title":"Thymus changes in anti-MuSK-positive and -negative myasthenia gravis","volume":"64","author":"Lauriola","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib6","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.clinph.2005.06.003","article-title":"MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns","volume":"116","author":"Stickler","year":"2005","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.jaut.2013.12.005_bib7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/01.LAB.0000028144.48023.9B","article-title":"Anti-p110 autoantibodies identify a subtype of \u201cseronegative\u201d myasthenia gravis with prominent oculobulbar involvement","volume":"82","author":"Scuderi","year":"2002","journal-title":"Lab Invest"},{"key":"10.1016\/j.jaut.2013.12.005_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.jaut.2013.12.005_bib9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1083\/jcb.200307164","article-title":"MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction","volume":"165","author":"Cartaud","year":"2004","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.jaut.2013.12.005_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.biocel.2010.10.008","article-title":"Muscle specific kinase: organiser of synaptic membrane domains","volume":"43","author":"Ghazanfari","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jaut.2013.12.005_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib12","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1212\/WNL.0b013e318237f660","article-title":"Anti-MuSK autoantibodies block binding of collagen Q to MuSK","volume":"77","author":"Kawakami","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib13","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.21371","article-title":"Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction","volume":"63","author":"Cole","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06808.x","article-title":"Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis","volume":"1275","author":"Plomp","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaut.2013.12.005_bib15","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jneuroim.2007.01.010","article-title":"Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures","volume":"185","author":"Farrugia","year":"2007","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to Rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"201-202","author":"Illa","year":"2008","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1196\/annals.1254.057","article-title":"A\u00a0simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score","volume":"998","author":"Sanders","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaut.2013.12.005_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cyto.a.21015","article-title":"SPICE: exploration and analysis of post-cytometric complex multivariate datasets","volume":"79","author":"Roederer","year":"2011","journal-title":"Cytometry A"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.jaut.2013.12.005_bib22","doi-asserted-by":"crossref","first-page":"iii26","DOI":"10.1136\/ard.2008.098004","article-title":"Th17 cells in immunity and autoimmunity","volume":"67","author":"Oukka","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.005_bib23","first-page":"819467","article-title":"Th17 response and inflammatory autoimmune diseases","volume":"2012","author":"Waite","year":"2012","journal-title":"Int J Inflam"},{"key":"10.1016\/j.jaut.2013.12.005_bib24","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jaut.2013.12.005_bib25","doi-asserted-by":"crossref","first-page":"7602","DOI":"10.4049\/jimmunol.0901881","article-title":"CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis","volume":"183","author":"Fletcher","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nri1840","article-title":"Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases","volume":"6","author":"Pantaleo","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaut.2013.12.005_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jneuroim.2006.05.017","article-title":"Major pathogenic effects of anti-MuSK antibodies in myasthenia gravis","volume":"177","author":"Boneva","year":"2006","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib29","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib30","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1468-1331.2007.01870.x","article-title":"Clinical and experimental features of MuSK antibody positive MG in Japan","volume":"14","author":"Ohta","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ana.20341","article-title":"Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis","volume":"57","author":"Shiraishi","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib33","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1212\/WNL.44.9.1732","article-title":"Treatment of myasthenia gravis with anti-CD4 antibody: improvement correlates to decreased T-cell autoreactivity","volume":"44","author":"Ahlberg","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib34","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1212\/WNL.29.5.734","article-title":"Cellular immune response to acetylcholine receptor in myasthenia gravis: II. Thymectomy and corticosteroids","volume":"29","author":"Morgutti","year":"1979","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/WNL.40.4.581","article-title":"Immune studies in human immunodeficiency virus infection with myasthenia gravis: a case report","volume":"40","author":"Nath","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1212\/WNL.52.3.484","article-title":"Myasthenia in SCID mice grafted with myasthenic patient lymphocytes: role of CD4+ and CD8+ cells","volume":"52","author":"Wang","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1405.042","article-title":"CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"1132","author":"Conti-Fine","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaut.2013.12.005_bib38","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000069079","article-title":"Interleukin-2 production by peripheral blood mononuclear cells from patients with myasthenia gravis","volume":"49","author":"Utsugisawa","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib39","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mus.22070","article-title":"Increased serum interleukin-17 levels in patients with myasthenia gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaut.2013.12.005_bib40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaut.2013.12.005_bib41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-2-44","article-title":"Myasthenia gravis","volume":"2","author":"Juel","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaut.2013.12.005_bib42","article-title":"Treatment strategies for myasthenia gravis: an update","volume":"13","author":"Diaz-Manera","year":"1873","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaut.2013.12.005_bib43","first-page":"427","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib44","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib45","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0198-8859(99)00062-2","article-title":"A\u00a0susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C","volume":"60","author":"Janer","year":"1999","journal-title":"Human Immunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib46","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.57.9.1555","article-title":"Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies","volume":"57","author":"Giraud","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib47","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/jnnp.56.4.382","article-title":"Association of HLA-Bw46DR9 combination with juvenile myasthenia gravis in Chinese","volume":"56","author":"Chen","year":"1993","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.jaut.2013.12.005_bib48","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1172\/JCI114724","article-title":"HLA antigens in Japanese patients with myasthenia gravis","volume":"86","author":"Matsuki","year":"1990","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaut.2013.12.005_bib49","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1196\/annals.1405.027","article-title":"Genetic factors in autoimmune myasthenia gravis","volume":"1132","author":"Giraud","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaut.2013.12.005_bib50","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/01.wnl.0000218159.79769.5c","article-title":"Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5","volume":"66","author":"Niks","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib51","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1212\/01.wnl.0000339103.08830.86","article-title":"HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5","volume":"72","author":"Bartoccioni","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0165-5728(00)00250-2","article-title":"T\u00a0cell recognition of muscle acetylcholine receptor in ocular myasthenia gravis","volume":"108","author":"Wang","year":"2000","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0165-5728(98)00146-5","article-title":"CD4+ T cell repertoire on the epsilon subunit of muscle acetylcholine receptor in myasthenia gravis","volume":"91","author":"Wang","year":"1998","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib54","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1073\/pnas.87.19.7792","article-title":"Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis","volume":"87","author":"Protti","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaut.2013.12.005_bib55","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1172\/JCI117050","article-title":"Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects","volume":"93","author":"Moiola","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaut.2013.12.005_bib56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0165-5728(94)90044-2","article-title":"Acetylcholine receptor-reactive T cells in myasthenia gravis: evidence for the involvement of different subpopulations of T helper cells","volume":"50","author":"Yi","year":"1994","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib57","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00915723","article-title":"Immunopathogenesis and treatment of myasthenia gravis","volume":"7","author":"Levinson","year":"1987","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib58","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ana.410190119","article-title":"Suppressor T cells in myasthenia gravis and antibodies to acetylcholine receptor","volume":"19","author":"Lisak","year":"1986","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib59","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1212\/WNL.31.9.1198","article-title":"Polyclonal B-cell activity in myasthenia gravis","volume":"31","author":"Levinson","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib60","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1212\/WNL.34.6.802","article-title":"In\u00a0vitro synthesis of antibodies to acetylcholine receptor by peripheral blood\u00a0cells: role of suppressor T cells in normal subjects","volume":"34","author":"Lisak","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib61","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jneuroim.2013.09.006","article-title":"Disturbed B cell subpopulations and increased plasma cells in myasthenia gravis patients","volume":"264","author":"Kohler","year":"2013","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib62","doi-asserted-by":"crossref","unstructured":"Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L et\u00a0al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol;17:893\u2013902.","DOI":"10.1111\/j.1468-1331.2010.03019.x"},{"key":"10.1016\/j.jaut.2013.12.005_bib63","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1212\/WNL.0b013e3181d31e47","article-title":"Undiminished regulatory T cells in the thymus of patients with myasthenia gravis","volume":"74","author":"Matsui","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib64","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10875-012-9685-0","article-title":"Changes of Treg-associated molecules on CD4+CD25\u00a0+Treg cells in myasthenia gravis and effects of immunosuppressants","volume":"32","author":"Xu","year":"2012","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clim.2012.09.012","article-title":"Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low\/-) T cells in patients with myasthenia gravis","volume":"145","author":"Thiruppathi","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib66","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2567.2005.02220.x","article-title":"Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment","volume":"116","author":"Fattorossi","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.jaut.2013.12.005_bib67","first-page":"54","article-title":"Circulating CD4+CD25+ T regulatory and natural killer T cells in patients with myasthenia gravis: a flow cytometry study","volume":"19","author":"Battaglia","year":"2005","journal-title":"J\u00a0Biol Regul Homeost Agents"},{"key":"10.1016\/j.jaut.2013.12.005_bib68","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clim.2007.10.001","article-title":"Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis","volume":"126","author":"Li","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib69","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2010.03.016","article-title":"Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients","volume":"225","author":"Masuda","year":"2010","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib70","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.imlet.2008.11.015","article-title":"The role of FoxP3+CD4+CD25hi Tregs in the pathogenesis of myasthenia gravis","volume":"122","author":"Zhang","year":"2009","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jaut.2013.12.005_bib71","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","article-title":"Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis","volume":"105","author":"Balandina","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2013.12.005_bib72","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2249.2007.03442.x","article-title":"Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas","volume":"149","author":"Scarpino","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib73","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.20340","article-title":"Selective loss of regulatory T cells in thymomas","volume":"56","author":"Strobel","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0165-5728(94)90080-9","article-title":"Augmented interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in blood mononuclear cells in myasthenia gravis","volume":"51","author":"Link","year":"1994","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib75","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0165-5728(93)90055-4","article-title":"Immune activation in myasthenia gravis: soluble interleukin-2 receptor, interferon-gamma and tumor necrosis factor-alpha levels in patients' serum","volume":"48","author":"Confalonieri","year":"1993","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib76","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410300110","article-title":"Serum interleukin-2 concentrations in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis","volume":"30","author":"Hartung","year":"1991","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib77","first-page":"474","article-title":"[Interleukin-2 production by peripheral blood mononuclear cell from patients with myasthenia gravis\u2013correlation with clinical severity]","volume":"32","author":"Utsugisawa","year":"1992","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.jaut.2013.12.005_bib78","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0165-5728(94)00183-O","article-title":"Transforming growth factor-beta 1 suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis","volume":"58","author":"Link","year":"1995","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib79","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2249.1999.01062.x","article-title":"Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG)","volume":"118","author":"Huang","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib80","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.4049\/jimmunol.153.7.3353","article-title":"Idiotype- and anti-idiotype-reactive T lymphocytes in myasthenia gravis. Evidence for the involvement of different subpopulations of T helper lymphocytes","volume":"153","author":"Yi","year":"1994","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib81","first-page":"934","article-title":"[Detection of interleukin-6 in serum and cerebrospinal fluid of patients with neuroimmunological diseases]","volume":"42","author":"Shimada","year":"1993","journal-title":"Arerugi"},{"key":"10.1016\/j.jaut.2013.12.005_bib82","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ana.410350211","article-title":"Organ-specific autoantigens induce transforming growth factor-beta mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis","volume":"35","author":"Link","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib83","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.05.010","article-title":"Serum BAFF expression in patients with myasthenia gravis","volume":"199","author":"Kim","year":"2008","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib84","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archneur.65.10.1358","article-title":"A\u00a0potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis","volume":"65","author":"Ragheb","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib85","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib86","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jneuroim.2012.11.003","article-title":"The increased expression of CD21 on AchR specified B cells in patients with myasthenia gravis","volume":"256","author":"Yin","year":"2013","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib87","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1212\/01.WNL.0000128048.23930.1D","article-title":"Are MuSK antibodies the primary cause of myasthenic symptoms?","volume":"62","author":"Selcen","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib88","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.410220205","article-title":"Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study","volume":"22","author":"Schluep","year":"1987","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib89","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2353\/ajpath.2007.070240","article-title":"Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status","volume":"171","author":"Leite","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaut.2013.12.005_bib90","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1212\/WNL.31.8.935","article-title":"Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology","volume":"31","author":"Scadding","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.005_bib91","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2249.1991.tb05625.x","article-title":"Individual germinal centres of myasthenia gravis human thymuses contain polyclonal activated B cells that express all the Vh and Vk families","volume":"83","author":"Guigou","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib92","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib93","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0046-8177(91)90132-9","article-title":"In situ production of interleukins in hyperplastic thymus from myasthenia gravis patients","volume":"22","author":"Emilie","year":"1991","journal-title":"Human Pathol"},{"key":"10.1016\/j.jaut.2013.12.005_bib94","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1749-6632.1993.tb22873.x","article-title":"High IL-6 gene expression and production by cultured human thymic epithelial cells from patients with myasthenia gravis","volume":"681","author":"Cohen-Kaminsky","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaut.2013.12.005_bib95","first-page":"121","article-title":"Interleukin-6 overproduction by cultured thymic epithelial cells from patients with myasthenia gravis is potentially involved in thymic hyperplasia","volume":"4","author":"Cohen-Kaminsky","year":"1993","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.jaut.2013.12.005_bib96","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF00918185","article-title":"In\u00a0vitro interleukin-1 (IL-1) production in thymic hyperplasia and thymoma from patients with myasthenia gravis","volume":"11","author":"Aime","year":"1991","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib97","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1074\/jbc.M109.047423","article-title":"Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells","volume":"285","author":"Mandapathil","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaut.2013.12.005_bib98","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cellimm.2011.06.010","article-title":"T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus","volume":"271","author":"Loza","year":"2011","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jaut.2013.12.005_bib99","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaut.2013.12.005_bib100","first-page":"968","article-title":"Rituximab in refractory MuSK antibody myasthenia gravis","volume":"254","author":"Thakre","year":"2007","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.jaut.2013.12.005_bib101","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841113001522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841113001522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:10:19Z","timestamp":1760256619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841113001522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":100,"alternative-id":["S0896841113001522"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2013.12.005","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2013.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}